Tim Greten

Title: Tim Greten: Innovator in Immune Response Modulation

Introduction

Tim Greten is a prominent inventor based in Baltimore, MD (US). He has made significant contributions to the field of immunology, particularly in the development of innovative methods to detect and modulate immune responses. With a total of 2 patents, Greten's work is at the forefront of advancing our understanding of T cell-dependent immune mechanisms.

Latest Patents

Greten's latest patents focus on the use of multivalent chimeric peptide-loaded, MHC/Ig molecules. These inventions aim to detect, activate, or suppress antigen-specific T cell-dependent immune responses. The first patent describes the construction of divalent peptide/MHC complexes using a recombinant DNA strategy. This involves ligating DNA encoding MHC class I to DNA coding for murine Ig heavy chain. The resulting MHC/Ig complexes are designed to load peptides of interest homogeneously. Flow cytometry results indicate that these complexes bind specifically and with high affinity to cells bearing their cognate receptors. Furthermore, these MHC/Ig complexes are valuable for studying TCR/MHC interactions and lymphocyte tracking, serving as specific regulators of immune responses.

Career Highlights

Tim Greten is affiliated with Johns Hopkins University, where he continues to push the boundaries of research in immunology. His work has garnered attention for its potential applications in therapeutic settings, particularly in enhancing the efficacy of immune responses.

Collaborations

Greten collaborates with notable colleagues, including Jonathan Schneck and Drew M Pardoll. Their combined expertise contributes to the advancement of research in immune modulation and therapeutic strategies.

Conclusion

Tim Greten's innovative work in the field of immunology exemplifies the impact of research on understanding and manipulating immune responses. His patents represent significant advancements that could lead to new therapeutic approaches in medicine.